Top Stock Picks for the Week of July 9th

Genomic Health, Inc. GHDX, is a global life science company focused on genomic-based clinical diagnostic tests for cancer. Over the past three months, Genomic Health has been outperforming its industry. The stock has gained 62.6%, as compared with the industry’s 8.1% gain. Analysts are encouraged by the year-over-year rise in the company's revenues, driven by solid performance in the United States and internationally. Over the past 60 days, its earnings estimates have been revised upward for 2018. Genomic continues to make significant progress with its Oncotype DX breast cancer test. Positive result related to Oncotype DX Genomic Prostate Score also buoys optimism.

United Healthcare Group Inc. UNH, is a diversified health and well-being company. Shares of UnitedHealth Group have outperformed the industry year to date. The company's robust Government business and continued strong performance at Optum are driving long-term growth. Its international business and strong capital position driving business investment are the other positives. The company raised its 2018 financial outlook, banking on the business strength, compelling products and services and diversified medical market positions. It also has grown its revenues consistently over the past several years. UnitedHealth has a healthy balance sheet with unparalleled financial flexibility.  

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Genomic Health, Inc. (GHDX) : Free Stock Analysis Report
 
UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research